Literature DB >> 19645698

Risk-group-specific dose finding based on an average toxicity score.

B Nebiyou Bekele1, Yisheng Li, Yuan Ji.   

Abstract

We propose a Bayesian dose-finding design that accounts for two important factors, the severity of toxicity and heterogeneity in patients' susceptibility to toxicity. We consider toxicity outcomes with various levels of severity and define appropriate scores for these severity levels. We then use a multinomial-likelihood function and a Dirichlet prior to model the probabilities of these toxicity scores at each dose, and characterize the overall toxicity using an average toxicity score (ATS) parameter. To address the issue of heterogeneity in patients' susceptibility to toxicity, we categorize patients into different risk groups based on their susceptibility. A Bayesian isotonic transformation is applied to induce an order-restricted posterior inference on the ATS. We demonstrate the performance of the proposed dose-finding design using simulations based on a clinical trial in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645698      PMCID: PMC4570736          DOI: 10.1111/j.1541-0420.2009.01297.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

1.  Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.

Authors:  A T Legedza; J G Ibrahim
Journal:  Stat Med       Date:  2001-03-30       Impact factor: 2.373

2.  Bayesian inference on order-constrained parameters in generalized linear models.

Authors:  David B Dunson; Brian Neelon
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

3.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

4.  Bivariate isotonic design for dose-finding with ordered groups.

Authors:  Anastasia Ivanova; Kai Wang
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

5.  Monitoring the rates of composite events with censored data in phase II clinical trials.

Authors:  Ying Kuen Cheung; Peter F Thall
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

6.  Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Authors:  Yisheng Li; B Nebiyou Bekele; Yuan Ji; John D Cook
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

7.  Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Authors:  André Rogatko; James S Babb; Hao Wang; Michael J Slifker; Gary R Hudes
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

8.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

9.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

10.  Monitoring late-onset toxicities in phase I trials using predicted risks.

Authors:  B Nebiyou Bekele; Yuan Ji; Yu Shen; Peter F Thall
Journal:  Biostatistics       Date:  2007-12-14       Impact factor: 5.899

View more
  6 in total

1.  Continual reassessment method with multiple toxicity constraints.

Authors:  Shing M Lee; Bin Cheng; Ying Kuen Cheung
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

2.  Sequential designs for individualized dosing in phase I cancer clinical trials.

Authors:  Xuezhou Mao; Ying Kuen Cheung
Journal:  Contemp Clin Trials       Date:  2016-08-31       Impact factor: 2.226

3.  Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.

Authors:  Zhengjia Chen; Mourad Tighiouart; Jeanne Kowalski
Journal:  Contemp Clin Trials       Date:  2012-04-25       Impact factor: 2.226

4.  Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.

Authors:  Zhengjia Chen; Ye Cui; Taofeek K Owonikoko; Zhibo Wang; Zheng Li; Ruiyan Luo; Michael Kutner; Fadlo R Khuri; Jeanne Kowalski
Journal:  Contemp Clin Trials       Date:  2014-02-12       Impact factor: 2.226

5.  Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.

Authors:  Beibei Guo; Yisheng Li
Journal:  Stat Med       Date:  2014-11-21       Impact factor: 2.373

6.  Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.

Authors:  Zhengjia Chen; Zhibo Wang; Haibin Wang; Taofeek K Owonikoko; Jeanne Kowalski; Fadlo R Khuri
Journal:  Open Med Inform J       Date:  2013-04-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.